AngioDynamics Inc
NASDAQ:ANGO

Watchlist Manager
AngioDynamics Inc Logo
AngioDynamics Inc
NASDAQ:ANGO
Watchlist
Price: 10.9 USD -3.28% Market Closed
Market Cap: $449.3m

EV/EBITDA

132
Current
192%
More Expensive
vs 3-y median of 45.2

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
132
=
Enterprise Value
$439.2m
/
EBITDA
$3.2m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
132
=
Enterprise Value
$439.2m
/
EBITDA
$3.2m

Valuation Scenarios

AngioDynamics Inc is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (45.2), the stock would be worth $3.73 (66% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-90%
Maximum Upside
No Upside Scenarios
Average Downside
74%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 132 $10.9
0%
3-Year Average 45.2 $3.73
-66%
5-Year Average 63.6 $5.25
-52%
Industry Average 12.9 $1.06
-90%
Country Average 14.4 $1.19
-89%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$439.2m
/
Dec 2025
$3.2m
=
132
Current
$439.2m
/
May 2026
$9.5m
=
46
Forward
$439.2m
/
May 2027
$15.9m
=
27.7
Forward
$439.2m
/
May 2028
$38.5m
=
11.4
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
US
AngioDynamics Inc
NASDAQ:ANGO
453.2m USD 132 -16.4
US
Abbott Laboratories
NYSE:ABT
180.6B USD 15.9 27.7
US
Intuitive Surgical Inc
NASDAQ:ISRG
160.7B USD 42.6 56.3
US
Stryker Corp
NYSE:SYK
125.2B USD 19.7 38.6
IE
Medtronic PLC
NYSE:MDT
111.8B USD 13.4 24.2
US
Boston Scientific Corp
NYSE:BSX
102.6B USD 20.8 35.4
US
Edwards Lifesciences Corp
NYSE:EW
46.1B USD 23.6 43
DE
Siemens Healthineers AG
XETRA:SHL
41B EUR 10.8 19.1
US
IDEXX Laboratories Inc
NASDAQ:IDXX
44.5B USD 29.8 42
US
Becton Dickinson and Co
NYSE:BDX
44B USD 9.9 25
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
31.6B USD 11 15.1

Market Distribution

Higher than 93% of companies in the United States of America
Percentile
93rd
Based on 9 875 companies
93rd percentile
132
Low
0 — 10
Typical Range
10 — 21.5
High
21.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 10
Median 14.4
70th Percentile 21.5
Max 1 767 274.1

AngioDynamics Inc
Glance View

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 800 full-time employees. The company went IPO on 2004-05-27. Its devices are used in minimally invasive, image-guided procedures. Its product offerings include Endovascular Therapies, Oncology/Surgery (OS) and Vascular Access (VA). Its Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products (Core) and Venous Insufficiency. Its OS product offerings includes a range of ablation technologies, including thermal tissue ablation systems, surgical resection and the Irreversible Electroporation (IRE) technology, the NanoKnife System. Its portfolio of VA products includes peripherally inserted central catheters (PICCs), midline catheters, implantable ports, dialysis catheters and related accessories and supplies.

ANGO Intrinsic Value
6.21 USD
Overvaluation 43%
Intrinsic Value
Price
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett